It is important to have financial discussions early and often with patients and framing the conversation in the right way, said Yousuf Zafar, MD, MHS, of the Duke Cancer Institute and a member of the Association of Community Cancer Centers Financial Advocacy Network Advisory Committee.
It is important to have financial discussions early and often with patients and framing the conversation in the right way, said Yousuf Zafar, MD, MHS, of the Duke Cancer Institute and a member of the Association of Community Cancer Centers Financial Advocacy Network Advisory Committee.
Transcript
How do financial advocates or financial navigators integrate into a care team?
Financial advocates play an incredibly important role in this process. A lot of it has to do with bringing to the table a set of knowledge that they can really apply to help patients, to understand what resources are available to them, to help them prepare for costs, and to act as a liaison between the clinician and the patient such that the clinician can really help in terms of making appropriate clinical decisions and the financial advocate can help in assisting the patient afford those treatments.
How should discussions of financial distress and planning be incorporated into a patient’s cancer journey?
I think that affordability discussions should happen early. I’m not completely sure, yet, who should be having that discussion: whether the clinician should have that discussion, or the financial advocate should have the discussion first. But, what I do know is, as a clinician, my responsibility is to make sure that my patient can tolerate their treatment both from a physical perspective and from a financial perspective.
And, so, in my practice, I will often ask patients questions like, “Are you able to afford your treatment?” And if they say, “No,” I then direct them to our financial care counselors. I think that conversation needs to happen not just early, but often.
During financial conversations, are patients open and willing to discuss what they can’t afford?
I think more and more patients understand that cost has to be a part of their decision making if they want to stay on their treatment and be able to afford it. The trick comes in how that conversation is couched.
So for me, I am very careful to let patients understand that I am asking this question not because I’m interested in reimbursement or, even at that moment, not that I’m interested in the overall economic well-being of the health system. But what I’m interested in is being able to help the patient in front of me be able to afford their care. Afford the care that I think is the best for them. And that’s how I couch that discussion, to make it as easy as possible for the patient. To remove all risk of embarrassment or misunderstanding on the part of the patient.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access
March 12th 2025Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More